Managing Waldenström’s macroglobulinemia with BTK inhibitors

Bruton’s tyrosine kinase (BTK) inhibition is one of the treatment standards for patients with relapsed/refractory Waldenström’s macroglobulinemia (WM) and for patients with WM who are unsuitable for immunochemotherapy (ICT). It offers deep and durable responses with a manageable safety profile that...

Descripción completa

Detalles Bibliográficos
Autores principales: Buske, Christian, Jurczak, Wojciech, Salem, Joe-Elie, Dimopoulos, Meletios A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883164/
https://www.ncbi.nlm.nih.gov/pubmed/36402930
http://dx.doi.org/10.1038/s41375-022-01732-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883164/
https://www.ncbi.nlm.nih.gov/pubmed/36402930
http://dx.doi.org/10.1038/s41375-022-01732-9

Ejemplares similares